The availability of our team to support you has not changed as a result of COVID-19. If there is a way we can assist you, we are here to help - Contact us

Horizon Discovery Group plc Re. Share Price Movement

16 Apr 2014

Horizon Discovery Group plc (“Horizon” or “the Company”), the revenue generating life science company supplying research tools to organisations engaged in genomics research and the development of personalised medicines, comments on the recent share price movement below.

“Horizon continues to trade strongly since the IPO, at least in line with expectations and we are actively pursuing the Company’s stated strategy to make strategic acquisitions and expanding our IP portfolio, geographic footprint, sales and distribution channels.” stated Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc.

For further information please contact:

Consilium Strategic Communications

Amber Bielecka / Mary-Jane Elliott / Jessica Hodgson / Matthew Neal

horizon@consilium-comms.com

+44 207 920 2352

Panmure Gordon and Co.

As Nominated Adviser and Broker

Corporate Finance

Freddy Crossley / Duncan Monteith / Fred Walsh

Broking

Tom Salvesen/ Adam Pollock

Tel: +44 20 7886 2500

About Horizon Discovery Group plc

Horizon is a revenue-generating life science company supplying research tools to organizations engaged in genomics research and the development of personalized medicines. Horizon has a diverse and international customer base approaching 800 organizations, including major pharmaceutical, biotechnology and diagnostic companies as well as leading academic research centres. The Company supplies its products and services into multiple markets, estimated to total in excess of £29 billion by 2015.

Horizon’s core capabilities are built around its proprietary translational genomics platform, GENESIS™, a high-precision and flexible suite of gene editing tools. Horizon has applied GENESIS™ to create over 500 X-MAN™ cell lines, accurately modeling the disease-causing mutations found in genetically based diseases. These ‘patients-in-a-test-tube’ are being used by customers to identify the effect of individual or compound genetic mutations on drug activity, patient responsiveness, and resistance, which may lead to the successful prediction of which patient sub-groups will respond to currently-available and future drug treatments.